Key points
- Emyria achieved 191% increase in yearly revenue for FY26
- Total number of clinics operational increased by 475%
- Expansion plans include additional reimbursement pathways and international opportunities
Full summary
Emyria Ltd held a year-end presentation for investors, highlighting a 191% increase in yearly revenue for FY26. The company expanded its clinic network, increasing the number of operational clinics by 475%. Emyria also announced the launch of the Empax Global Partnership Program, government payer access, and a Medibank agreement. The company is well-positioned to leverage the growing momentum in global psychedelic drug treatments and plans to continue expanding its Australian clinic network, pursue additional reimbursement pathways, and explore opportunities in New Zealand and the USA.
Guidance
Emyria expects to increase clinic utilisation and expand its Australian clinic network in FY27.
Outlook
Emyria is optimistic about leveraging the growing momentum in global psychedelic drug treatments and plans to expand its operations both domestically and internationally.